📰 Multicenter Study News
Page 2 - Multicenter Study News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Multicenter Study. Real-time updates on events, politics, business and more.
September 12, 2023
Medical imaging Artificial Intelligence company Qure.ai has announced that its AI-enabled Chest X-ray solution for Pneumothorax and Pleural Effusion has received 510(k) clearance from the U.S. Food and Drug Administration (FDA).
June 28, 2023
Aurora Spine has enrolled the first patient in its multicenter study of the Dexa-C cervical interbody system. Study will analyze data from 80 cases and Dexa
June 20, 2023
LX9211 is an investigational, non-opioid treatment for diabetic peripheral neuropathic pain
June 18, 2023
Mallinckrodt plc (NYSE American: MNK), a global specialty pharmaceutical company, today announced the publication of findings from a retrospective, observational, single arm, European chart review study assessing the real-world use of extracorporeal photopheresis (ECP) and its impact on clinical outcomes in the modern era of heart transplantation.1 An online version of the data manuscript – the largest-known study of ECP in heart transplant patients – is currently published on the ...
June 13, 2023
- Results from the largest European and first multicenter, retrospective, observational chart review study investigating the real-world use of ECP in heart transplant patients reinforce its
June 1, 2023
- Eight Presentations on Yescarta and TecartusAdvance Kite's Cell Therapy Leadership - - New Data Highlight Magrolimab's Potential to Alter the Tumor Microenvironment - Gilead Sciences, Inc. (Nasdaq:
June 1, 2023
– Eight Presentations on Yescarta® and Tecartus® Advance Kite’s Cell Therapy Leadership – – New Data Highlight Magrolimab’s Potential to Alter the Tumor... | June 1, 2023
May 28, 2023
/PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter) today announced that the updated results of Phase Ib study of its CSF-1R...
May 12, 2023
A class of drugs used for their ability to stop tumor cells from dividing is now under study for their potential to reduce the pain and damage caused by sickle cell disease, investigators report.
February 20, 2023
Takeda (TSE:4502/NYSE:TAK) today announced late-breaking data from the Phase 3 GRAPHITE study presented at the 2023 Tandem Meetings, demonstrating vedolizumab achieved a statistically significant and clinically meaningful improvement in lower gastrointestinal (GI) aGvHD-free survival by Day 180 after allo-HSCT with no relevant differences in safety profile versus placebo.1